SYN - Synthetic Biologics, Inc.
| Previous Close | 0.4348 |
| Open | 0.4300 |
| Bid | 0.4262 x 900 |
| Ask | 0.0000 x 1300 |
| Day's Range | 0.4288 - 0.4540 |
| 52 Week Range | 0.3700 - 0.8500 |
| Volume | 206,767 |
| Avg. Volume | 231,945 |
| Market Cap | 7.795M |
| Beta (5Y Monthly) | 1.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7830 |
| Earnings Date | Feb 19, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.25 |
- GlobeNewswire
Results in line with outlook
• Revenue for the fourth quarter of 2019 amounted to ISK 4,935 million, a decrease of 9% from the same period in 2018. • The quarter’s EBITDA amounted to ISK 1,409 million, compared to ISK 1,449 million in the fourth quarter of 2018. The EBITDA margin was 28.6% in the fourth quarter of 2019 compared to 26.7% in the same quarter last year.
- Thomson Reuters StreetEvents
Edited Transcript of SYN earnings conference call or presentation 20-Feb-20 9:30pm GMT
Q4 2019 Synthetic Biologics Inc Earnings Call
- PR Newswire
Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the year ended December 31, 2019.
- PR Newswire
Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the NYSE American LLC (the "Exchange") has accepted the Company's plan of compliance (the "Plan") for continued listing on the Exchange.
- Simply Wall St.
We Think Synthetic Biologics (NYSEMKT:SYN) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- PR Newswire
Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced the receipt of official meeting minutes from the U.S. Food and Drug Administration (FDA) following a Type C meeting held on December 2, 2019 at the Company's request to discuss the development of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients who are administered intravenous (IV) beta-lactam antibiotics in response to fever.
- GlobeNewswire
Sýn hf.: Financial calendar 2020
Sýn will host its Annual General Meeting and publish its interim condensed and annual consolidated financial statements according to the below financial calendar: Interim.
- GlobeNewswire
Sýn hf.: Landsdowne Partners International Limited - Major shareholder announcements
See attachment: Attachment Landsdowne_SYN_24.12.2019
- Insider Monkey
Is Synthetic Biologics Inc (SYN) Going To Burn These Hedge Funds ?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
- PR Newswire
Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it has received written communication from NYSE American LLC (the "Exchange"), the Company's current listing exchange, stating that it is not in compliance with certain continued listing standards as set forth in the NYSE American Company Guide. Based on the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2019, which was filed with the Securities and Exchange Commission (SEC) on November 4, 2019, the Company is below compliance with Part 10, Section 1003 of the NYSE American Company Guide since it reported stockholders' equity of $4.9 million and net losses in five of its most recent fiscal years as of September 30, 2019.
- Thomson Reuters StreetEvents
Edited Transcript of SYN earnings conference call or presentation 4-Nov-19 9:30pm GMT
Q3 2019 Synthetic Biologics Inc Earnings Call
- GlobeNewswire
Sýn hf.: Best operating profit of the year
At the beginning of the year, the accounting treatment of broadcasting license rights was changed, amounts for 2018 have been restated. EBITDA for the first nine months of 2019 was ISK 4,100 million, a decrease of ISK 153 million from same period in 2018. Profit in the first nine months of the year amounted to ISK 384 million which is an increase of ISK 135 million from same period in 2018.
- PR Newswire
Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results
-- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C -- -- Conference Call Today, November 4, 2019, at 4:30 p.m. (EST) -- ROCKVILLE, Md. , Nov. ...
- PR Newswire
Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019
-- Conference Call Scheduled for Monday, November 4, 2019 at 4:30 p.m. ET -- ROCKVILLE, Md. , Oct. 28, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage ...
- PR Newswire
Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
ROCKVILLE, Md., Sept. 26, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Office (USPTO) has granted a U.S. patent and issued a Notice of Allowance for a patent application covering various aspects of the clinical SYN-010 program. Recently granted U.S. Patent No. 10,328,151, which is co-owned by Synthetic Biologics and Cedars-Sinai Medical Center (CSMC) and exclusively licensed to Synthetic Biologics, covers the composition of matter of the SYN-010 clinical agent.
- Simply Wall St.
Does The Synthetic Biologics, Inc. (NYSEMKT:SYN) Share Price Tend To Follow The Market?
If you own shares in Synthetic Biologics, Inc. (NYSEMKT:SYN) then it's worth thinking about how it contributes to the...
- Thomson Reuters StreetEvents
Edited Transcript of SYN earnings conference call or presentation 8-Aug-19 8:30pm GMT
Q2 2019 Synthetic Biologics Inc Earnings Call
- GlobeNewswire
Sýn hf.: Financial results below expectations but positive outlook
Sýn´s Q2 2019 financial statement was approved by Sýn´s CEO and Board of Directors at a board meeting on August 28, 2019. At the beginning of the year, the accounting treatment of broadcasting license rights was changed. Broadcasting license rights was classified as inventory but as of January 1, 2019, it is classified as intangible assets.
- GlobeNewswire
Sýn hf.: Change in guidance
After changes in management, which occurred in the first half of the year, a new financial forecast has been implemented. The forecasted EBITDA will be lowered since revenues in telecom and media are forecasted close to 400 million lower and cost of media content and distribution are estimated 160 million higher. The previous forecast for free cash flow is unchanged but it is clear the result will be at the lower end of the 1,6-2,0 bn range. Management has made changes to the financial reporting process of each division and strengthen its key control procedures, which will lead to better forecasting going forward. Measures taken this summer, which will be realized at the end of the year, have lowered the cost basis of the company.
- PR Newswire
Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results
-- Announced Clinical Trial Agreement with Washington University School of Medicine to Conduct a Phase 1b /2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients ...
- PR Newswire
Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019
-- Conference Call Scheduled for Thursday, August 8, 2019 at 4:30 p.m. ET -- ROCKVILLE, Md. , Aug. 1, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...
- PR Newswire
Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards
ROCKVILLE, Md., July 1, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today receipt, on June 28, 2019, of notification from the NYSE American LLC (the "Exchange") that the Company has regained compliance with Part 10, Section 1003 of the NYSE American's Company Guide (the "Company Guide") relating to the Exchange's continued listing requirements. The Company previously received notification from the NYSE American citing failure to comply with the minimum stockholders' equity continued listing standard as set forth in Part 10, Section 1003 of the Company Guide.
- Simply Wall St.
Those Who Purchased Synthetic Biologics (NYSEMKT:SYN) Shares Three Years Ago Have A 99% Loss To Show For It
As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a while...
- GlobeNewswire
Sýn hf.: Notification of related party trading
See attachment: Attachment NOMX - Viðskipti fjárhagslega tengds aðila 24 05 2019
